Please enable Javascript
Nicolas Girard, MD, PhD
Articles by Nicolas Girard, MD, PhD
Dr. Girard Discusses PALOMA-2 at 2024 American Society of Clinical Oncology Annual Meeting
Nicolas Girard, MD, PhD
ASCO 2024: Focus on Lung Cancer
|
June 12, 2024
The phase 2 trial evaluated subcutaneous amivantamab and lazertinib as a first-line therapy for EGFR-mutated NSCLC.
View More